Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance

[1]  H. Hsieh,et al.  Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery , 2014 .

[2]  A. Shaw,et al.  ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. , 2014, Clinical advances in hematology & oncology : H&O.

[3]  F. Khuri,et al.  Second-generation ALK inhibitors: filling the non "MET" gap. , 2014, Cancer discovery.

[4]  C. Gridelli,et al.  ALK inhibitors in the treatment of advanced NSCLC. , 2014, Cancer treatment reviews.

[5]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[6]  Sungjoon Kim,et al.  Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 , 2013, Journal of medicinal chemistry.

[7]  Y. Ohe,et al.  CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. , 2013, The Lancet. Oncology.

[8]  A. Saeed,et al.  Journey of the ALK-inhibitor CH5424802 to phase II clinical trial , 2013, Archives of pharmacal research.

[9]  R. Roskoski,et al.  Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. , 2013, Pharmacological research.

[10]  J. Cui,et al.  Chapter Twenty-Five - Case History: Xalkori™ (Crizotinib), a Potent and Selective Dual Inhibitor of Mesenchymal Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) for Cancer Treatment , 2013 .

[11]  Tatiana G. Kutateladze,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[12]  Takuo Tsukuda,et al.  Anaplastic Lymphoma Kinase Inhibitors for the Treatment of ALK-Positive Cancers , 2012 .

[13]  Jeffrey W. Clark,et al.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.

[14]  H. Sakamoto,et al.  9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors. , 2011, Journal of medicinal chemistry.

[15]  J. Christensen,et al.  Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). , 2011, Journal of medicinal chemistry.

[16]  Hiroshi Sakamoto,et al.  CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. , 2011, Cancer cell.

[17]  A. Shaw,et al.  Targeting Anaplastic Lymphoma Kinase in Lung Cancer , 2011, Clinical Cancer Research.

[18]  Young Lim Choi,et al.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.

[19]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[20]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[21]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.